Collaboration

#Boehringer Ingelheim #Cancer research #Collaboration #Diabetes #Drug development #Drug discovery #Eli Lilly #HIV #Lung cancer #Neurodevelopmental disorders #Precision medicine #Rare disease

DDW Highlights podcast shares five new stories

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry news.  ‘Teamwork makes the dream work’ this week, with the launch of… Read More

#News

Enzymes
#Biologics / Biotechnology #Collaboration #Enzymes #High throughput screening #Partnership #Synthetic biology

Partnership hopes to accelerate protein discovery

GenScript Biotech, a provider of life-science research tools and services, is partnering with Allozymes, a Singapore-based biotech startup, with aims to accelerate the enzyme discovery and development process.  In the partnership, GenScript will provide the mutant libraries construction and expression, while Allozymes will provide ultra-high-throughput screening for… Read More

#News

#Boehringer Ingelheim #Cancer research #Collaboration #Diabetes #Drug development #Drug discovery #Eli Lilly #HIV #Lung cancer #Neurodevelopmental disorders #Precision medicine #Rare disease

This week in drug discovery (5-9 December)

News round-up for 5-9 December by DDW Digital Content Editor Diana Spencer. ‘Teamwork makes the dream work’ this week, with the launch of new partnerships to further the development of precision drugs in neurodevelopmental disorders, lung cancer and rare paediatric diseases. The benefits of collaboration have also been… Read More

#News

#Biologics / Biotechnology #Cancer research #Collaboration #Europe #Gene therapy #Lung cancer

International consortium launches €12.8 million lung cancer project

Irish biotech company OmniSpirant and French biotech EVerZom have joined other partners to launch INSPIRE, a €12.8 million lung cancer project funded by Horizon Europe.   The project gathers European partners spanning across biotechnology, medical devices, cancer research, academia and patient advocacy. Over the next three years, the consortium… Read More

#Cancer Research #News

#AI #AI / data analytics / healthtech / informatics #Collaboration #Genetics / genomics #Neurodevelopmental disorders #Neurology #Precision medicine #Rare disease

Partnership hopes to advance precision drug development

A new partnership between industry and three rare disease foundations has formed with the goal of accelerating the development of precision drugs to treat rare neurodevelopmental disorders.  AI-driven genomics company Genomenon will partner with COMBINEDBrain, SynGAP Research Fund, and SLC-6A1 Connect and their pharma partners to deliver… Read More

#News

#Cell and gene therapy #Collaboration #Drug delivery #Drug discovery

Partnership hopes to improve large-scale exosome production

Bio-chromatography company Sartorius BIA Separations (BIA) and exosomes medicines company Exopharm have signed a Material Transfer Agreement and associated collaborative programme.  The partnership aims to combine Exopharm’s LEAP technology together with BIA’s CIM (Convective Interaction Media) monolith chromatography for improved large-scale therapeutic exosome production and commercialisation.  The companies hope to… Read More

#Business & Investment #News

CST antibodies using the Cell DIVE multiplexed imaging solution
#Antibodies #Biomarkers #Cancer research #Collaboration #Drug discovery #Partnership

New antibody validation partnership hopes to “power scientific discovery” 

Leica Microsystems and Cell Signaling Technology (CST) have agreed a partnership to validate CST antibodies on the Cell DIVE multiplexed imaging solution.  As an open multiplexing system, Cell DIVE allows researchers to design custom antibody biomarker panels.  James O’Brien, Vice President Life Sciences at Leica Microsystems, said: “Instead of spending… Read More

#Business & Investment #News

Cancer research lab
#Academic #Cancer #Cancer research #Cancer Research Horizons #Cancer Research UK #Collaboration #Oncology

Academic-industry collaboration extends cancer drug alliance 

Cancer Research UK’s innovation engine, Cancer Research Horizons, and Newcastle University, have agreed an extension of their strategic drug discovery alliance with Astex Pharmaceuticals.  The alliance will continue to focus on the discovery of potential new cancer drugs with associated biomarkers, with the aim of providing an… Read More

#Cancer Research #News

Quantum computing
#Collaboration #Life sciences #Quantum computing

Quantum computing collaboration could help slash drug discovery cost 

Algorithmiq, a Helsinki-based quantum computing start-up, has entered into an engagement with IBM to progress in its exploration of quantum algorithms that attempt to solve complex issues in life sciences.   Between IBM’s hardware, software and quantum applications expertise and Algorithmiq’s algorithm developers, the companies hope to explore… Read More

#News

#Biotechnology #Collaboration #Drug targets #Therapeutics

Collaboration to stabilise a challenging drug target  

Swedish biotech company Salipro Biotech has entered into a research collaboration and license agreement with Sanofi on the discovery of therapeutic biologics against a challenging drug target.  The collaboration brings together Salipro Biotech’s services in developing stable antigens of GPCRs, ion channels and transporters via its proprietary… Read More

#News

Map of Europe
#CNS #Collaboration #European Medicines Agency #License agreement #Orphan drugs

Alliance will provide a new therapy for rare CNS disease 

Minoryx and Neuraxpharm have agreed a strategic alliance to provide a new therapy for rare CNS disease patients in Europe.  The companies have entered into a license agreement for the European rights to leriglitazone, currently under European Medicines Agency (EMA) review for the orphan indication X-linked Adrenoleukodystrophy… Read More

#News

Man using microscope in lab
#Collaboration #Phenotyping #PhoreMost #Protein binders #Therapeutic targets

PhoreMost enters multi-target collaboration with Arvinas

PhoreMost and targeted protein degradation (TPD) specialists Arvinas have agreed a multi-target collaboration. Under the terms of the agreement, PhoreMost will deploy its phenotypic screening platform, SITESEEKER, toward multiple high-value therapeutic targets. The output from SITESEEKER screening campaigns will be used to drive degrader drug discovery in oncology and neurodegeneration… Read More

#Business & Investment #News

#Advanced Therapies Europe #CAR-T #Cell and gene therapy #Cell therapy #Collaboration

On the European CGT landscape, zebras and the future of medicine

Listen to this article on the DDW podcast: Alongside industry professionals interested in the cell and gene therapy landscape in Europe, DDW’s Multimedia Editor Megan Thomas was welcomed to Advanced Therapies Europe 2022 by Phacilitate’s Vice President, Becky Johnson-Kent. Johnson-Kent introduced the notion of the zebra company and compared its two-fold… Read More

#Editor's Choice #Exclusive Content

#Collaboration #Cystic fibrosis #Neuropsychiatric disorders #RNA #Therapeutics

Latest episode of the DDW Highlights podcast

The latest episode of the DDW Highlights podcast is now available for download. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  This round-up was compiled by DDW’s Diana Spencer. Amid continued… Read More

#News

Japanese flag
#Biopharmaceutical #Collaboration #Drug discovery #Healthcare #Investment #Life sciences #Market reporting #Start-ups

A review of Japan’s drug discovery landscape  

DDW Multimedia Editor Megan Thomas takes a broad look at the drug discovery and development landscape in Japan and highlights how it is bolstered by government policies, investment, collaboration, start-up ecosystems and academic research.   Japan continues to be one of the largest pharmaceutical markets in the world, despite what the… Read More

#Business & Investment #Editor's Choice #Exclusive Content #Market Reports #Trends & Analysis